Featuring both online and offline service modules ranging from follow-up visits and consultation with doctors to interpretation of data reports and popularization of disease knowledge, the platform is expected to offer patients efficient, convenient, and integrated chronic disease management services, and enhance their experience even without visiting hospitals.

Jemincare is committed to delivering CKD patients with a better experience in drug use, diagnosis, and treatment by offering services outside hospitals throughout the course of the disease. Boasting a series of proven tools devised to improve patient management services, Waterdrop Patient Platform, built on a patient-centric approach, can provide patients with services in the whole disease course outside hospitals. The bilateral cooperation is of positive significance in helping CKD patients solve problems associated with diagnosis, drug use, and daily care during the long cycle of treatment.

According to Yao Hu, co-founder of Waterdrop and General Manager of Waterdrop's Pharmaceutical Innovation Business Unit, Waterdrop Patient Platform enjoys a solid foundation in offering patient services across the whole disease course outside hospitals and has put in place a multi-dimensional operation system that provides patients with one-on-one Q&A services related to reporting interpretation, drug use, disease knowledge explanation, nutrition & lifestyle guidance, and psychological support. As of September 2022, the platform had served 3 million patients with severe diseases and set up nearly 1,600 communities that covered patients of 12 common serious diseases and rare diseases. "Centering on patient needs, Waterdrop Patient Platform will further optimize service processes to bring more comprehensive, professional, and considerate services to patients. Also, empowered by digital technologies, the platform can help pharmaceutical partners boost quality and efficiency."